Chronic Inducible Urticaria

Immunology·MeSH: Chronic Inducible Urticaria

10 drugs in development·7 companies·6 clinical trials

Drug Pipeline by Phase

Phase 3(3)

Drug	Company
Barzolvolimab (CDX-0159)	Celldex Therapeutics, Inc. (CLDX)
remibrutinib dose a	Novartis AG (NVS)
remibrutinib dose b	Novartis AG (NVS)

Phase 2(4)

Drug	Company
barzolvolimab	Celldex Therapeutics, Inc. (CLDX)
briquilimab	Jasper Therapeutics Inc. (JSPR)
oral evo756 300 mg qd	Evommune, Inc. (EVMN)
oral evo756 50 mg bid	Evommune, Inc. (EVMN)

Phase 1(3)

Drug	Company
blu-808	Blueprint Medicines Corp (BPMC)
EDP-978	ENANTA PHARMACEUTICALS INC (ENTA)
thb001	Third Harmonic Bio, Inc. (THRD)

BioSniper tracks 10 drugs in development for Chronic Inducible Urticaria across 7 companies.

There are 6 clinical trials targeting Chronic Inducible Urticaria tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.